VANGUARD GROUP INC 13D and 13G filings for Rocket Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 12:59 pm Sale | 2026-03-13 | 13G | ROCKET PHARMACEUTICALS INC RCKT | VANGUARD GROUP INC | 0 0.000% | -8,544,423 (Position Closed) | Filing |
| 2026-01-30 2:46 pm Purchase | 2025-12-31 | 13G | ROCKET PHARMACEUTICALS INC RCKT | VANGUARD GROUP INC | 8,544,423 7.890% | 3,096,858 (+56.85%) | Filing |
| 2024-02-13 5:14 pm Purchase | 2023-12-29 | 13G | ROCKET PHARMACEUTICALS INC RCKT | VANGUARD GROUP INC | 5,447,565 6.040% | 1,261,023 (+30.12%) | Filing |
| 2023-02-09 11:32 am Purchase | 2022-12-30 | 13G | ROCKET PHARMACEUTICALS INC RCKT | VANGUARD GROUP INC | 4,186,542 5.320% | 885,404 (+26.82%) | Filing |
| 2022-02-10 08:37 am Purchase | 2021-12-31 | 13G | ROCKET PHARMACEUTICALS INC RCKT | VANGUARD GROUP INC | 3,301,138 5.120% | 3,301,138 (New Position) | Filing |